Paper33333207
Identification of a novel long-acting 4'-modified nucleoside reverse transcriptase inhibitor against HBV.
Higashi-Kuwata N and 16 others. J Hepatol, 2021. Cited by 26 papers, by iCite.
Cite this record
ConductScience Library. Identification of a novel long-acting 4'-modified nucleoside reverse transcriptase inhibitor against HBV. Papers, record 33333207. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33333207
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Drug Development | Major topic |
| Drug Resistance, Viral | Major topic |
| Hepatitis B | Major topic |
| Hepatitis B virus | Major topic |
| Reverse Transcriptase Inhibitors | Major topic |
| Animals | |
| Delayed-Action Preparations | |
| Disease Models, Animal | |
| Drug Administration Routes | |
| Drug Administration Schedule | |
| Humans | |
| Mice | |
| RNA-Directed DNA Polymerase | |
| Time |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| ZIA BC011486 | Intramural NIH HHS | United States | ZIABC011486 | PubMed and NIH | NIH RePORTER |
| ZIDSC007202 | NIH | NIH RePORTER |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 33715896 | Is there any need for new, long-acting nucleos(t)ide analogues for the treatment of hepatitis B infection? | https://conductscience.org/library/papers/33715896 |
Source PubMed
References17
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26122273 | 4'-modified nucleoside analogs: potent inhibitors active against entecavir-resistant hepatitis B virus. | Hepatology | 2015 | https://conductscience.org/library/papers/26122273 | PubMed |
| 2 | 27489345 | Structural basis of HIV inhibition by translocation-defective RT inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA). | Proc Natl Acad Sci U S A | 2016 | https://conductscience.org/library/papers/27489345 | PubMed |
| 3 | 29877316 | Hepatitis B virus infection. | Nat Rev Dis Primers | 2018 | https://conductscience.org/library/papers/29877316 | PubMed |
| 4 | 18056280 | Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition. | Antimicrob Agents Chemother | 2008 | https://conductscience.org/library/papers/18056280 | PubMed |
| 5 | 10815717 | Stability study of selected adenosine nucleosides using LC and LC/MS analyses. | J Pharm Biomed Anal | 2000 | https://conductscience.org/library/papers/10815717 | PubMed |
| 6 | 2106581 | Acid-stable 2'-fluoro purine dideoxynucleosides as active agents against HIV. | J Med Chem | 1990 | https://conductscience.org/library/papers/2106581 | PubMed |
| 7 | 17050790 | Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects. | J Clin Pharmacol | 2006 | https://conductscience.org/library/papers/17050790 | PubMed |
| 8 | 31266626 | Drugs in the Pipeline for HBV. | Clin Liver Dis | 2019 | https://conductscience.org/library/papers/31266626 | PubMed |
| 9 | 31168360 | Treatment for Advanced Hepatocellular Carcinoma: Current Standard and the Future. | Clin Liver Dis (Hoboken) | 2019 | https://conductscience.org/library/papers/31168360 | PubMed |
| 10 | 31266617 | WHO Guidelines for Prevention, Care and Treatment of Individuals Infected with HBV: A US Perspective. | Clin Liver Dis | 2019 | https://conductscience.org/library/papers/31266617 | PubMed |
| 11 | 30670420 | CMCdG, a Novel Nucleoside Analog with Favorable Safety Features, Exerts Potent Activity against Wild-Type and Entecavir-Resistant Hepatitis B Virus. | Antimicrob Agents Chemother | 2019 | https://conductscience.org/library/papers/30670420 | PubMed |
| 12 | 26515673 | Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones. | J Infect | 2016 | https://conductscience.org/library/papers/26515673 | PubMed |
| 13 | 2477299 | Inhibition of duck hepatitis B virus replication by 2',3'-dideoxycytidine. A potent inhibitor of reverse transcriptase. | Gastroenterology | 1989 | https://conductscience.org/library/papers/2477299 | PubMed |
| 14 | 2436223 | Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2',3'-dideoxynucleosides in vitro. | Proc Natl Acad Sci U S A | 1987 | https://conductscience.org/library/papers/2436223 | PubMed |
| 15 | 16968952 | Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. | Pharmacol Rev | 2006 | https://conductscience.org/library/papers/16968952 | PubMed |
| 16 | 27916488 | Human organic anion transporter 2 is an entecavir, but not tenofovir, transporter. | Drug Metab Pharmacokinet | 2017 | https://conductscience.org/library/papers/27916488 | PubMed |
| 17 | 17548498 | Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine. | Antimicrob Agents Chemother | 2007 | https://conductscience.org/library/papers/17548498 | PubMed |
Cited by20
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 26 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40872772 | The Evolution of Cell Culture Systems to Study Hepatitis B Virus Pathogenesis and Antiviral Susceptibility. | Viruses | 2025 | https://conductscience.org/library/papers/40872772 | PubMed |
| 39831159 | An orally available P1'-5-fluorinated Mpro inhibitor blocks SARS-CoV-2 replication without booster and exhibits high genetic barrier. | PNAS Nexus | 2025 | https://conductscience.org/library/papers/39831159 | PubMed |
| 39107264 | Colchicine-mediated selective autophagic degradation of HBV core proteins inhibits HBV replication and HBV-related hepatocellular carcinoma progression. | Cell Death Discov | 2024 | https://conductscience.org/library/papers/39107264 | PubMed |
| 38977798 | Deviated binding of anti-HBV nucleoside analog E-CFCP-TP to the reverse transcriptase active site attenuates the effect of drug-resistant mutations. | Sci Rep | 2024 | https://conductscience.org/library/papers/38977798 | PubMed |
| 38549051 | Predictors of antiretroviral treatment failure to the first line therapy: a cross-sectional study among Iranian HIV-positive adults. | BMC Infect Dis | 2024 | https://conductscience.org/library/papers/38549051 | PubMed |
| 38042824 | The role of Traditional Chinese medicine in anti-HBV: background, progress, and challenges. | Chin Med | 2023 | https://conductscience.org/library/papers/38042824 | PubMed |
| 37627273 | Chronic Hepatitis B Infection: New Approaches towards Cure. | Biomolecules | 2023 | https://conductscience.org/library/papers/37627273 | PubMed |
| 37265996 | Synthesis of novel entecavir analogues having 4'-cyano-6''-fluoromethylenecyclopentene skeletons as an aglycone moiety as highly potent and long-acting anti-hepatitis B virus agent. | RSC Adv | 2023 | https://conductscience.org/library/papers/37265996 | PubMed |
| 36933835 | A novel anti-HBV agent, E-CFCP, restores Hepatitis B virus (HBV)-induced senescence-associated cellular marker perturbation in human hepatocytes. | Virus Res | 2023 | https://conductscience.org/library/papers/36933835 | PubMed |
| 36906663 | Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure. | Drugs | 2023 | https://conductscience.org/library/papers/36906663 | PubMed |
| 36841831 | Identification of SARS-CoV-2 Mpro inhibitors containing P1' 4-fluorobenzothiazole moiety highly active against SARS-CoV-2. | Nat Commun | 2023 | https://conductscience.org/library/papers/36841831 | PubMed |
| 36563152 | An ultralong-acting tenofovir ProTide nanoformulation achieves monthslong HBV suppression. | Sci Adv | 2022 | https://conductscience.org/library/papers/36563152 | PubMed |
| 36410388 | Long-Acting Treatments for Hepatitis B. | Clin Infect Dis | 2022 | https://conductscience.org/library/papers/36410388 | PubMed |
| 36344041 | Effects of a novel hepatitis B anti-viral drug E-CFCP in renal organic acid transporters. | J Pharmacol Sci | 2022 | https://conductscience.org/library/papers/36344041 | PubMed |
| 36338434 | Potent and biostable inhibitors of the main protease of SARS-CoV-2. | iScience | 2022 | https://conductscience.org/library/papers/36338434 | PubMed |
| 35891374 | Drug Discovery Study Aimed at a Functional Cure for HBV. | Viruses | 2022 | https://conductscience.org/library/papers/35891374 | PubMed |
| 35308231 | A Polysaccharide From Eupolyphaga sinensis Walker With Anti-HBV Activities In Vitro and In Vivo. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/35308231 | PubMed |
| 35045629 | [A possible mechanism for low-level viremia occurrence in nucleos(t)ide analog-treated chronic hepatitis B patients]. | Zhonghua Gan Zang Bing Za Zhi | 2021 | https://conductscience.org/library/papers/35045629 | PubMed |
| 34829806 | The Hepatitis B Virus Nucleocapsid-Dynamic Compartment for Infectious Virus Production and New Antiviral Target. | Biomedicines | 2021 | https://conductscience.org/library/papers/34829806 | PubMed |
| 33572409 | Drug Discovery of Nucleos(t)ide Antiviral Agents: Dedicated to Prof. Dr. Erik De Clercq on Occasion of His 80th Birthday. | Molecules | 2021 | https://conductscience.org/library/papers/33572409 | PubMed |
Genes7
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ALB | 213 | PubTator's text mining | https://conductscience.org/library/genes/213 | NCBI Gene |
| IFNA1 | 3439 | PubTator's text mining | https://conductscience.org/library/genes/3439 | NCBI Gene |
| IFNL1 | 282618 | PubTator's text mining | https://conductscience.org/library/genes/282618 | NCBI Gene |
| IFNL2 | 282616 | PubTator's text mining | https://conductscience.org/library/genes/282616 | NCBI Gene |
| IFNL3 | 282617 | PubTator's text mining | https://conductscience.org/library/genes/282617 | NCBI Gene |
| PLAU | 5328 | PubTator's text mining | https://conductscience.org/library/genes/5328 | NCBI Gene |
| TAF8 | 129685 | PubTator's text mining | https://conductscience.org/library/genes/129685 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33333207
GET https://conductscience.org/api/papers/v1/33333207/authors